Immunotherapy and cell therapy have revolutionized the field of cancer treatment by harnessing the power of the immune system to fight cancer cells. However, the development of effective immunotherapy drugs such as immune checkpoint inhibitors requires extensive preclinical testing to ensure safety and efficacy. Breakthroughs in the field are faced with several challenges including the generation of appropriate humanized mouse models for preclinical evaluation. Among others, genetically-engineered mouse models have emerged as valuable tools for improving cancer treatment outcomes.
July 13, 2023
- Advancing Preclinical Research in Gynecologic Cancers
- History of CAR T-cells and Their Continued Use in Hematological Malignancies to Advance Next-Generation Therapies
- Cancer Support: Contract Research Organizations, More Than a Vendor, a Partner In Drug Development.
- Advancing Bone and Sarcoma Cancer Research Through Robust In Vivo Models
- How the FDA’s Plausible Mechanism Framework Signals the Future of Precision Oncology
Advancing Preclinical Research in Gynecologic Cancers
Gynecologic cancers, including endometrial and ovarian cancers, remain areas of high unmet need. Advances in targeted therapy, immunotherapy, ...
History of CAR T-cells and Their Continued Use in Hematological Malignancies to Advance Next-Generation Therapies
CAR T-cell therapy originated in the late 1980s, first-generation constructs lacked adequate co-stimulatory signaling, causing poor CAR T-cell ...
Cancer Support: Contract Research Organizations, More Than a Vendor, a Partner In Drug Development.
Developing cancer therapies is an incredibly complex, costly, and highly regulated journey. To navigate this challenging terrain, pharmaceutical and ...
Get Started
Contact Us Today!
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
